Yesintek (Ustekinumab-Kfce) for Psoriasis

Overview
Yesintek is approved by the U.S. Food and Drug Administration (FDA) for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis. It is indicated for adults and children 6 and older who are candidates for phototherapy or systemic therapy. Yesintek is also known by its drug name, ustekinumab-kfce. The drug is a biosimilar to Stelara (ustekinumab), which means it has demonstrated to be highly similar to Stelara with no clinically meaningful differences in terms of safety, purity, or potency. Yesintek is also known by its drug name, ustekinumab-kfce.

Yesintek belongs to a class of medications called interleukin (IL)-12 and IL-23 antagonists. It works by blocking specific proteins in the immune system that contribute to inflammation, helping to reduce symptoms of psoriasis and psoriatic arthritis, including skin lesions and joint pain.

How do I take it?
Prescribing information states that Yesintek is administered as a subcutaneous (under the skin) injection. Dosing depends on the recipient’s weight. For children and adults, a recipient generally receives their second dose at week four following their initial dose. Subsequent doses are generally administered every 12 weeks. Yesintek should always be administered as prescribed by a health care provider.

Side effects
Common side effects of Yesintek include nasopharyngitis (cold symptoms), upper respiratory tract infection, headache, and fatigue.

Rare but serious side effects may include serious infections, tuberculosis, malignancies (cancers), hypersensitivity reactions (such as anaphylaxis), noninfectious pneumonia, and posterior reversible encephalopathy syndrome (a neurological condition). 

For more information about this treatment, visit:

Yesintek (Ustekinumab-Kfce) Injection, for Subcutaneous or Intravenous Use — U.S. Food and Drug Administration

FDA Approves Yesintek, Sixth Stelara Biosimilar; Launch Slated for February — Healio